Results 221 to 230 of about 164,505 (264)

Immunotherapy for Acute Myeloid Leukemia

Seminars in Hematology, 2015
Despite longstanding efforts in basic research and clinical studies, the prognosis for patients with acute myeloid leukemia (AML) remains poor. About half of the patients are not medically fit for intensive induction therapy to induce a complete remission and are treated with palliative treatment concepts.
Lichtenegger, F.S., Krupka, C., Köhnke, T., Subklewe, M.   +3 more
openaire   +3 more sources

Immunotherapy of Acute Myeloid Leukemia

Current Pharmaceutical Biotechnology, 2001
Most patients with acute myeloid leukemia (AML) respond initially to combination chemotherapy but later relapse. These patients often die from progressive disease or toxicities of further chemotherapy. At relapse, the patients' blasts are usually resistant to the drugs to which the patient has been exposed and frequently to other cytotoxic agents as ...
A E, Frankel, M R, Baer, D E, Hogge, R K, Stuart   +3 more
openaire   +2 more sources

Acute myeloid leukemia in adults

Current Treatment Options in Oncology, 2000
The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire   +2 more sources

Transplantation in Acute Myeloid Leukemia

Hematology/Oncology Clinics of North America, 2014
Acute myeloid leukemia (AML) is associated with poor outcome mainly because of relapse. The best antileukemic treatment is allogeneic stem cell transplantation. However, the associated significant nonrelapse mortality limits both the application and outcome of the procedure.
Tsila, Zuckerman, Jacob M, Rowe
openaire   +2 more sources

Angiogenesis in acute myeloid leukemia

Blood, 2000
We have read with interest the report of Padro et al[1][1] showing an increased angiogenesis in acute myeloid leukemia. Recently, other studies published in Blood also have shown that angiogenesis in acute myeloid leukemias is higher than in controls[2][2] and that it has an independent ...
DI RAIMONDO, FRANCESCO, G. A. PALUMBO, M. P. AZZARO, R. GIUSTOLISI   +3 more
openaire   +3 more sources

Pharmacogenomics in Acute Myeloid Leukemia

Pharmacogenomics, 2009
Acute myeloid leukemia (AML) in adults is a heterogeneous malignant pathology with a globally unfavorable prognosis. The classification of AML allows identification of subgroups with favorable prognosis. However, besides these specific subgroups, most patients will have an intermediate or unfavorable prognosis often resulting in induction failure ...
Christophe, Roumier, Meyling H, Cheok
openaire   +2 more sources

Immunophenotyping of Acute Myeloid Leukemia

2019
Immunophenotyping by multiparameter flow cytometry is a rapid and efficient technique to simultaneously assess and correlate multiple individual cell properties like size and internal complexity along with antigen expression in a population of cells. This method is utilized for rapid characterization of the blasts and classification of acute myeloid ...
Pallavi Kanwar, Galera, Chunjie, Jiang, Raul, Braylan   +2 more
openaire   +2 more sources

Tipifarnib in acute myeloid leukemia

Drugs of Today, 2007
Treatment of older patients with acute myeloid leukemia (AML) represents a significant challenge. There is little evidence that outcomes are improving for patients subjected to conventional intensive treatment. In addition, there is a large population of patients who are not considered fit for a more intensive treatment approach, and treatment options ...
Alan K, Burnett, Jonathan, Kell
openaire   +2 more sources

Adult Acute Myeloid Leukemia

Mayo Clinic Proceedings, 2006
Acute myeloid leukemia (AML) is a group of several different diseases, the treatment and outcome of which depend on several factors, including leukemia karyotype, patient age, and comorbid conditions. Despite advances in understanding the molecular biology of AML, its treatment remains challenging.
Elias J, Jabbour, Elihu, Estey, Hagop M, Kantarjian   +2 more
openaire   +2 more sources

Childhood Acute Myeloid Leukemia

Current Treatment Options in Oncology, 2008
Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire   +2 more sources